{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T02:27:09Z","timestamp":1794882429291,"version":"4.9.1"},"reference-count":87,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T00:00:00Z","timestamp":1788739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T00:00:00Z","timestamp":1788739200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Biotechnol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Drugs for aging-related diseases may modulate aging itself, but standard clinical trial designs cannot detect such effects. Aging clocks could close this gap, but epigenetic models often yield inconsistent, hard-to-interpret results. In contrast, proteomic clocks, by tracking the immediate effectors of biological change, may excel in providing aging biomarkers or mechanistic insight. Here we compare six proteomic clocks (ProtAge, OrganAge\n                    <jats:sub>mortality<\/jats:sub>\n                    , OrganAge\n                    <jats:sub>chrono<\/jats:sub>\n                    , PAC, ipfP3GPT and PAOPAC) on serum proteomes from a published 12-week phase 2a trial of the candidate anti-fibrotic drug rentosertib in idiopathic pulmonary fibrosis. We measure the variance between the clocks and find that all six clocks consistently predicted lower biological age in treated arms. However, proteomic clocks alone cannot deconvolute aging- and disease-specific effects. We addressed this issue indirectly through pathway analyses that identified potential anti-aging shifts in senescence and metabolic processes alongside the anti-fibrotic activity of rentosertib. This work supports the goal of dual-purpose clinical trial designs that integrate aging endpoints into studies for specific disease indications.\n                  <\/jats:p>","DOI":"10.1038\/s41587-026-03286-y","type":"journal-article","created":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T09:02:50Z","timestamp":1788771770000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Integration of proteomic aging clocks in a phase 2a clinical trial supports simultaneous geroprotective assessment"],"prefix":"10.1038","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7067-8966","authenticated-orcid":false,"given":"Alex","family":"Zhavoronkov","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5709-9529","authenticated-orcid":false,"given":"Fedor","family":"Galkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9157-9182","authenticated-orcid":false,"given":"Feng","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Aliper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikhail","family":"Durymanov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis","family":"Sidorenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9270-7139","authenticated-orcid":false,"given":"Jing-Dong J.","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9315-3406","authenticated-orcid":false,"given":"Xiaodong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuojun","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4597-9833","authenticated-orcid":false,"given":"Christoph","family":"Kuppe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0242-853X","authenticated-orcid":false,"given":"M.","family":"Austin Argentieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kejun","family":"Ying","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8285-7766","authenticated-orcid":false,"given":"Ludger J. E.","family":"Goeminne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6675-0566","authenticated-orcid":false,"given":"Mahdi","family":"Moqri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6215-190X","authenticated-orcid":false,"given":"Alexander","family":"Tyshkovskiy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0372-7016","authenticated-orcid":false,"given":"Vadim N.","family":"Gladyshev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,7]]},"reference":[{"key":"3286_CR1","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s10522-021-09910-5","volume":"22","author":"Z Li","year":"2021","unstructured":"Li, Z. et al. Aging and age-related diseases: from mechanisms to therapeutic strategies. Biogerontology 22, 165\u2013187 (2021).","journal-title":"Biogerontology"},{"key":"3286_CR2","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1038\/s41392-022-01251-0","volume":"7","author":"J Guo","year":"2022","unstructured":"Guo, J. et al. Aging and aging-related diseases: from molecular mechanisms to interventions and treatments. Signal Transduct. Target. Ther. 7, 391 (2022).","journal-title":"Signal Transduct. Target. Ther."},{"key":"3286_CR3","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1038\/s43587-021-00051-5","volume":"1","author":"HM D\u00f6nerta\u015f","year":"2021","unstructured":"D\u00f6nerta\u015f, H. M., Fabian, D. K., Fuentealba, M., Partridge, L. & Thornton, J. M. Common genetic associations between age-related diseases. Nat. Aging 1, 400\u2013412 (2021).","journal-title":"Nat. Aging"},{"key":"3286_CR4","first-page":"1911","volume":"17","author":"A Zhavoronkov","year":"2025","unstructured":"Zhavoronkov, A., Wilczok, D., Ren, F. & Galkin, F. Age-related diseases as a testbed for anti-aging therapeutics: the case of idiopathic pulmonary fibrosis. Aging 17, 1911\u20131928 (2025).","journal-title":"Aging"},{"key":"3286_CR5","doi-asserted-by":"publisher","DOI":"10.1111\/acel.13596","volume":"21","author":"AS Kulkarni","year":"2022","unstructured":"Kulkarni, A. S. et al. Geroscience-guided repurposing of FDA-approved drugs to target aging: a proposed process and prioritization. Aging Cell 21, e13596 (2022).","journal-title":"Aging Cell"},{"key":"3286_CR6","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.cell.2022.11.001","volume":"186","author":"C L\u00f3pez-Ot\u00edn","year":"2023","unstructured":"L\u00f3pez-Ot\u00edn, C., Blasco, M. A., Partridge, L., Serrano, M. & Kroemer, G. Hallmarks of aging: an expanding universe. Cell 186, 243\u2013278 (2023).","journal-title":"Cell"},{"key":"3286_CR7","doi-asserted-by":"publisher","first-page":"281","DOI":"10.18632\/aging.100034","volume":"1","author":"MV Blagosklonny","year":"2009","unstructured":"Blagosklonny, M. V. Validation of anti-aging drugs by treating age-related diseases. Aging 1, 281\u2013288 (2009).","journal-title":"Aging"},{"key":"3286_CR8","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.arr.2018.11.008","volume":"49","author":"F Galkin","year":"2019","unstructured":"Galkin, F., Zhang, B., Dmitriev, S. E. & Gladyshev, V. N. Reversibility of irreversible aging. Ageing Res. Rev. 49, 104\u2013114 (2019).","journal-title":"Ageing Res. Rev."},{"key":"3286_CR9","doi-asserted-by":"publisher","first-page":"R115","DOI":"10.1186\/gb-2013-14-10-r115","volume":"14","author":"S Horvath","year":"2013","unstructured":"Horvath, S. DNA methylation age of human tissues and cell types. Genome Biol 14, R115\u2013R115 (2013).","journal-title":"Genome Biol"},{"key":"3286_CR10","doi-asserted-by":"publisher","first-page":"1487260","DOI":"10.3389\/fragi.2024.1487260","volume":"5","author":"M Min","year":"2024","unstructured":"Min, M., Egli, C., Dulai, A. S. & Sivamani, R. K. Critical review of aging clocks and factors that may influence the pace of aging. Front. Aging 5, 1487260 (2024).","journal-title":"Front. Aging"},{"key":"3286_CR11","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1080\/17501911.2025.2603880","volume":"17","author":"AT Apsley","year":"2025","unstructured":"Apsley, A. T., Etzel, L., Ye, Q. & Shalev, I. From population science to the clinic? Limits of epigenetic clocks as personal biomarkers. Epigenomics 17, 1447\u20131461 (2025).","journal-title":"Epigenomics"},{"key":"3286_CR12","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1080\/17501911.2024.2373682","volume":"16","author":"EM Crimmins","year":"2024","unstructured":"Crimmins, E. M., Klopack, E. T. & Kim, J. K. Generations of epigenetic clocks and their links to socioeconomic status in the Health and Retirement Study. Epigenomics 16, 1031\u20131042 (2024).","journal-title":"Epigenomics"},{"key":"3286_CR13","doi-asserted-by":"publisher","DOI":"10.1111\/acel.70103","volume":"24","author":"M Fuentealba","year":"2025","unstructured":"Fuentealba, M. et al. Multi-omics analysis reveals biomarkers that contribute to biological age rejuvenation in response to single-blinded randomized placebo-controlled therapeutic plasma exchange. Aging Cell 24, e70103 (2025).","journal-title":"Aging Cell"},{"key":"3286_CR14","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1038\/s41576-024-00807-w","volume":"26","author":"AE Teschendorff","year":"2025","unstructured":"Teschendorff, A. E. & Horvath, S. Epigenetic ageing clocks: statistical methods and emerging computational challenges. Nat. Rev. Genet. 26, 350\u2013368 (2025).","journal-title":"Nat. Rev. Genet."},{"key":"3286_CR15","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.18632\/aging.206245","volume":"17","author":"J Mitteldorf","year":"2025","unstructured":"Mitteldorf, J. Methylation clocks for evaluation of anti-aging interventions. Aging 17, 1082\u20131090 (2025).","journal-title":"Aging"},{"key":"3286_CR16","doi-asserted-by":"publisher","first-page":"2450","DOI":"10.1038\/s41591-024-03164-7","volume":"30","author":"MA Argentieri","year":"2024","unstructured":"Argentieri, M. A. et al. Proteomic aging clock predicts mortality and risk of common age-related diseases in diverse populations. Nat. Med. 30, 2450\u20132460 (2024).","journal-title":"Nat. Med."},{"key":"3286_CR17","doi-asserted-by":"publisher","first-page":"101070","DOI":"10.1016\/j.arr.2020.101070","volume":"60","author":"AA Johnson","year":"2020","unstructured":"Johnson, A. A., Shokhirev, M. N., Wyss-Coray, T. & Lehallier, B. Systematic review and analysis of human proteomics aging studies unveils a novel proteomic aging clock and identifies key processes that change with age. Ageing Res. Rev. 60, 101070 (2020).","journal-title":"Ageing Res. Rev."},{"key":"3286_CR18","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1038\/s41586-023-06592-6","volume":"622","author":"BB Sun","year":"2023","unstructured":"Sun, B. B. et al. Plasma proteomic associations with genetics and health in the UK Biobank. Nature 622, 329\u2013338 (2023).","journal-title":"Nature"},{"key":"3286_CR19","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/s41514-025-00318-w","volume":"12","author":"S Lee-\u00d8deg\u00e5rd","year":"2025","unstructured":"Lee-\u00d8deg\u00e5rd, S., Austin Argentieri, M., Norheim, F., Drevon, C. A. & Birkeland, K. I. Reversal of proteomic aging with exercise\u2014results from the UK biobank and a 12-week intervention study. NPJ Aging 12, 19 (2025).","journal-title":"NPJ Aging"},{"key":"3286_CR20","doi-asserted-by":"publisher","first-page":"6358","DOI":"10.1016\/j.cell.2024.08.021","volume":"187","author":"Y Yang","year":"2024","unstructured":"Yang, Y. et al. Metformin decelerates aging clock in male monkeys. Cell 187, 6358\u20136378 (2024).","journal-title":"Cell"},{"key":"3286_CR21","doi-asserted-by":"publisher","first-page":"2475","DOI":"10.18632\/aging.203960","volume":"14","author":"FW Pun","year":"2022","unstructured":"Pun, F. W. et al. Hallmarks of aging-based dual-purpose disease and age-associated targets predicted using PandaOmics AI-powered discovery engine. Aging 14, 2475\u20132506 (2022).","journal-title":"Aging"},{"key":"3286_CR22","doi-asserted-by":"publisher","first-page":"2602","DOI":"10.1038\/s41591-025-03743-2","volume":"31","author":"Z Xu","year":"2025","unstructured":"Xu, Z. et al. A generative AI-discovered TNIK inhibitor for idiopathic pulmonary fibrosis: a randomized phase 2a trial. Nat. Med. 31, 2602\u20132610 (2025).","journal-title":"Nat. Med."},{"key":"3286_CR23","first-page":"2863","volume":"15","author":"A Olsen","year":"2023","unstructured":"Olsen, A. et al. Identification of dual-purpose therapeutic targets implicated in aging and glioblastoma multiforme using PandaOmics\u2014an AI-enabled biological target discovery platform. Aging 15, 2863 (2023).","journal-title":"Aging"},{"key":"3286_CR24","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1016\/j.tips.2024.04.010","volume":"45","author":"CY Ewald","year":"2024","unstructured":"Ewald, C. Y. et al. TNIK\u2019s emerging role in cancer, metabolism, and age-related diseases. Trends Pharmacol. Sci. 45, 478\u2013489 (2024).","journal-title":"Trends Pharmacol. Sci."},{"key":"3286_CR25","doi-asserted-by":"publisher","unstructured":"Ren, F. et al. A small-molecule TNIK inhibitor targets fibrosis in preclinical and clinical models. Nat. Biotechnol. 43, 63\u201375 https:\/\/doi.org\/10.1038\/s41587-024-02143-0 (2025).","DOI":"10.1038\/s41587-024-02143-0"},{"key":"3286_CR26","doi-asserted-by":"publisher","first-page":"102871","DOI":"10.1016\/j.arr.2025.102871","volume":"112","author":"J Chen","year":"2025","unstructured":"Chen, J. et al. From clock to clock: therapeutic target discovery for aging and age-related diseases. Ageing Res. Rev. 112, 102871 (2025).","journal-title":"Ageing Res. Rev."},{"key":"3286_CR27","doi-asserted-by":"publisher","first-page":"19121","DOI":"10.1021\/acs.jmedchem.4c01580","volume":"67","author":"V Aladinskiy","year":"2024","unstructured":"Aladinskiy, V. et al. Discovery of bis-imidazolecarboxamide derivatives as novel, potent, and selective TNIK inhibitors for the treatment of idiopathic pulmonary fibrosis. J. Med. Chem. 67, 19121\u201319142 (2024).","journal-title":"J. Med. Chem."},{"key":"3286_CR28","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adf7119","volume":"9","author":"TCP Pham","year":"2023","unstructured":"Pham, T. C. P. et al. TNIK is a conserved regulator of glucose and lipid metabolism in obesity. Sci. Adv. 9, eadf7119 (2023).","journal-title":"Sci. Adv."},{"key":"3286_CR29","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1056\/NEJMra003200","volume":"345","author":"TJ Gross","year":"2001","unstructured":"Gross, T. J. & Hunninghake, G. W. Idiopathic pulmonary fibrosis. N. Engl. J. Med. 345, 517\u2013525 (2001).","journal-title":"N. Engl. J. Med."},{"key":"3286_CR30","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1016\/S0002-9440(10)64282-4","volume":"162","author":"M Chilosi","year":"2003","unstructured":"Chilosi, M. et al. Aberrant Wnt\/\u03b2-catenin pathway activation in idiopathic pulmonary fibrosis. Am. J. Pathol. 162, 1495\u20131502 (2003).","journal-title":"Am. J. Pathol."},{"key":"3286_CR31","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1016\/S0140-6736(11)60052-4","volume":"378","author":"TE King","year":"2011","unstructured":"King, T. E., Pardo, A. & Selman, M. Idiopathic pulmonary fibrosis. Lancet 378, 1949\u20131961 (2011).","journal-title":"Lancet"},{"key":"3286_CR32","doi-asserted-by":"publisher","first-page":"e78156dc","DOI":"10.1097\/01.HS9.0000972260.78156.dc","volume":"7","author":"L Palombella","year":"2023","unstructured":"Palombella, L., Amrein, M., B\u00fchrer, E., Riether, C. & Ochsenbein, A. P1343: TNIK signalling impairs self-renewal and long-term reconstitution capacity of HSCS. HemaSphere 7, e78156dc (2023).","journal-title":"HemaSphere"},{"key":"3286_CR33","doi-asserted-by":"publisher","unstructured":"Kiessling, P. et al. Polyploid cardiomyocytes define disease-specific transcriptional states in the mammalian heart. Preprint at bioRxiv https:\/\/doi.org\/10.64898\/2026.01.31.701472 (2026).","DOI":"10.64898\/2026.01.31.701472"},{"key":"3286_CR34","unstructured":"InSilico Medicine Hong Kong Limited. Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT05975983 (2024)."},{"key":"3286_CR35","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.cmet.2024.10.005","volume":"37","author":"LJE Goeminne","year":"2025","unstructured":"Goeminne, L. J. E. et al. Plasma protein-based organ-specific aging and mortality models unveil diseases as accelerated aging of organismal systems. Cell Metab. 37, 205\u2013222 (2025).","journal-title":"Cell Metab."},{"key":"3286_CR36","doi-asserted-by":"publisher","DOI":"10.1111\/acel.14195","volume":"23","author":"C-L Kuo","year":"2024","unstructured":"Kuo, C.-L. et al. Proteomic aging clock (PAC) predicts age-related outcomes in middle-aged and older adults. Aging Cell 23, e14195 (2024).","journal-title":"Aging Cell"},{"key":"3286_CR37","first-page":"1999","volume":"17","author":"F Galkin","year":"2025","unstructured":"Galkin, F., Chen, S., Aliper, A., Zhavoronkov, A. & Ren, F. AI-driven toolset for IPF and aging research associates lung fibrosis with accelerated aging. Aging 17, 1999\u20132014 (2025).","journal-title":"Aging"},{"key":"3286_CR38","doi-asserted-by":"publisher","unstructured":"Xu, H., Chen, J., Chen, D., Mao, K. & Han, J.-D. J. Proteome-aware organ proxy aging clocks. Preprint at bioRxiv https:\/\/doi.org\/10.64898\/2026.04.24.720503 (2026).","DOI":"10.64898\/2026.04.24.720503"},{"key":"3286_CR39","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1164\/ajrccm.149.2.8306044","volume":"149","author":"DA Schwartz","year":"1994","unstructured":"Schwartz, D. A. et al. Determinants of survival in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 149, 450\u2013454 (1994).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"3286_CR40","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1164\/rccm.202301-0117OC","volume":"209","author":"JM Oldham","year":"2023","unstructured":"Oldham, J. M. et al. Proteomic biomarkers of survival in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 209, 1111\u20131120 (2023).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"3286_CR41","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1517\/14728222.2016.1111873","volume":"20","author":"R Ramasamy","year":"2016","unstructured":"Ramasamy, R., Shekhtman, A. & Schmidt, A. M. The multiple faces of RAGE\u2014opportunities for therapeutic intervention in aging and chronic disease. Expert Opin. Ther. Targets 20, 431\u2013446 (2016).","journal-title":"Expert Opin. Ther. Targets"},{"key":"3286_CR42","doi-asserted-by":"publisher","first-page":"689938","DOI":"10.3389\/fnins.2021.689938","volume":"15","author":"A Yuan","year":"2021","unstructured":"Yuan, A. & Nixon, R. A. Neurofilament proteins as biomarkers to monitor neurological diseases and the efficacy of therapies. Front. Neurosci. 15, 689938 (2021).","journal-title":"Front. Neurosci."},{"key":"3286_CR43","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/s10815-016-0663-y","volume":"33","author":"S Gunes","year":"2016","unstructured":"Gunes, S., Hekim, G. N. T., Arslan, M. A. & Asci, R. Effects of aging on the male reproductive system. J. Assist. Reprod. Genet. 33, 441\u2013454 (2016).","journal-title":"J. Assist. Reprod. Genet."},{"key":"3286_CR44","doi-asserted-by":"publisher","first-page":"3503","DOI":"10.1210\/en.2018-00601","volume":"159","author":"M Zaidi","year":"2018","unstructured":"Zaidi, M. et al. FSH, bone mass, body fat, and biological aging. Endocrinology 159, 3503\u20133514 (2018).","journal-title":"Endocrinology"},{"key":"3286_CR45","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1007\/s00198-024-07160-y","volume":"35","author":"DH Seo","year":"2024","unstructured":"Seo, D. H. et al. Chemokine CXCL9, a marker of inflammaging, is associated with changes of muscle strength and mortality in older men. Osteoporos. Int. 35, 1789\u20131796 (2024).","journal-title":"Osteoporos. Int."},{"key":"3286_CR46","first-page":"432","volume":"17","author":"Q Tang","year":"2025","unstructured":"Tang, Q. et al. AI-driven robotics laboratory identifies pharmacological TNIK inhibition as a potent senomorphic agent. Aging Dis 17, 432\u2013451 (2025).","journal-title":"Aging Dis"},{"key":"3286_CR47","doi-asserted-by":"publisher","first-page":"119","DOI":"10.3390\/biom13010119","volume":"13","author":"J Liu","year":"2023","unstructured":"Liu, J., Wang, F. & Luo, F. The role of JAK\/STAT pathway in fibrotic diseases: molecular and cellular mechanisms. Biomolecules 13, 119 (2023).","journal-title":"Biomolecules"},{"key":"3286_CR48","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-39786-7","volume":"14","author":"Y Rolland","year":"2023","unstructured":"Rolland, Y. et al. Challenges in developing Geroscience trials. Nat. Commun. 14, 5038 (2023).","journal-title":"Nat. Commun."},{"key":"3286_CR49","doi-asserted-by":"publisher","first-page":"820215","DOI":"10.3389\/fragi.2022.820215","volume":"3","author":"JL Nielsen","year":"2022","unstructured":"Nielsen, J. L., Bakula, D. & Scheibye-Knudsen, M. Clinical trials targeting aging. Front. Aging 3, 820215 (2022).","journal-title":"Front. Aging"},{"key":"3286_CR50","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1210\/endrev\/bnad008","volume":"44","author":"RC Baxter","year":"2023","unstructured":"Baxter, R. C. Signaling pathways of the insulin-like growth factor binding proteins. Endocr. Rev. 44, 753\u2013778 (2023).","journal-title":"Endocr. Rev."},{"key":"3286_CR51","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.54523","volume":"9","author":"N Alessio","year":"2020","unstructured":"Alessio, N. et al. Increase of circulating IGFBP-4 following genotoxic stress and its implication for senescence. eLife 9, e54523 (2020).","journal-title":"eLife"},{"key":"3286_CR52","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms14532","volume":"8","author":"MJ Schafer","year":"2017","unstructured":"Schafer, M. J. et al. Cellular senescence mediates fibrotic pulmonary disease. Nat. Commun. 8, 14532 (2017).","journal-title":"Nat. Commun."},{"key":"3286_CR53","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1038\/nrd.2018.234","volume":"18","author":"WEA de Witte","year":"2019","unstructured":"de Witte, W. E. A., Danhof, M., van der Graaf, P. H. & de Lange, E. C. M. The implications of target saturation for the use of drug\u2013target residence time. Nat. Rev. Drug Discov. 18, 84\u201384 (2019).","journal-title":"Nat. Rev. Drug Discov."},{"key":"3286_CR54","doi-asserted-by":"publisher","DOI":"10.1016\/j.vascn.2024.107570","volume":"131","author":"WS Redfern","year":"2025","unstructured":"Redfern, W. S. et al. Predicting clinical outcomes from off-target receptor interactions using Secondary IntelligenceTM. J. Pharmacol. Toxicol. Methods 131, 107570 (2025).","journal-title":"J. Pharmacol. Toxicol. Methods"},{"key":"3286_CR55","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2131\/jts.28.1","volume":"28","author":"Y Kanai","year":"2003","unstructured":"Kanai, Y. & Endou, H. Functional properties of multispecific amino acid transporters and their implications to transporter-mediated toxicity. J. Toxicol. Sci. 28, 1\u201317 (2003).","journal-title":"J. Toxicol. Sci."},{"key":"3286_CR56","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1016\/j.chembiol.2016.07.023","volume":"23","author":"KM Gayvert","year":"2016","unstructured":"Gayvert, K. M., Madhukar, N. S. & Elemento, O. A data-driven approach to predicting successes and failures of clinical trials. Cell Chem. Biol. 23, 1294\u20131301 (2016).","journal-title":"Cell Chem. Biol."},{"key":"3286_CR57","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1002\/cpt.1115","volume":"104","author":"R Evers","year":"2018","unstructured":"Evers, R. et al. Disease-associated changes in drug transporters may impact the pharmacokinetics and\/or toxicity of drugs: a white paper from the International Transporter Consortium. Clin. Pharmacol. Ther. 104, 900\u2013915 (2018).","journal-title":"Clin. Pharmacol. Ther."},{"key":"3286_CR58","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1124\/jpet.119.262972","volume":"372","author":"AD Rodrigues","year":"2020","unstructured":"Rodrigues, A. D. & Rowland, A. Profiling of drug-metabolizing enzymes and transporters in human tissue biopsy samples: a review of the literature. J. Pharmacol. Exp. Ther. 372, 308\u2013319 (2020).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"3286_CR59","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1016\/j.cell.2025.11.030","volume":"189","author":"Z Pang","year":"2026","unstructured":"Pang, Z. et al. Mapping cellular targets of covalent cancer drugs in the entire mammalian body. Cell 189, 725\u2013738 (2026).","journal-title":"Cell"},{"key":"3286_CR60","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.bbrc.2015.11.095","volume":"469","author":"D Kim","year":"2016","unstructured":"Kim, D., Lee, J., Lee, S., Park, J. & Lee, D. Predicting unintended effects of drugs based on off-target tissue effects. Biochem. Biophys. Res. Commun. 469, 399\u2013404 (2016).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"3286_CR61","doi-asserted-by":"publisher","first-page":"re6","DOI":"10.1126\/scisignal.2004652","volume":"6","author":"MJ Niederst","year":"2013","unstructured":"Niederst, M. J. & Engelman, J. A. Bypass mechanisms of resistance to receptor tyrosine kinase inhibition in lung cancer. Sci. Signal. 6, re6 (2013).","journal-title":"Sci. Signal."},{"key":"3286_CR62","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.omtm.2020.06.006","volume":"18","author":"Y Ilan","year":"2020","unstructured":"Ilan, Y. Overcoming compensatory mechanisms toward chronic drug administration to ensure long-term, sustainable beneficial effects. Mol. Ther. Methods Clin. Dev. 18, 335\u2013344 (2020).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"3286_CR63","doi-asserted-by":"publisher","first-page":"695","DOI":"10.3389\/fneur.2019.00695","volume":"10","author":"S Romano","year":"2019","unstructured":"Romano, S. et al. Drug holiday of interferon beta 1b in multiple sclerosis: a pilot, randomized, single blind study of non-inferiority. Front. Neurol. 10, 695 (2019).","journal-title":"Front. Neurol."},{"key":"3286_CR64","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1093\/gerona\/glw064","volume":"71","author":"SI Arriola Apelo","year":"2016","unstructured":"Arriola Apelo, S. I., Pumper, C. P., Baar, E. L., Cummings, N. E. & Lamming, D. W. Intermittent administration of rapamycin extends the life span of female C57BL\/6J mice. J. Gerontol. Ser. A 71, 876\u2013881 (2016).","journal-title":"J. Gerontol. Ser. A"},{"key":"3286_CR65","unstructured":"FDA\u2013NIH Biomarker Working Group. BEST (Biomarkers, EndpointS, and Other Tools) Resource (United States Food and Drug Administration, 2016)."},{"key":"3286_CR66","doi-asserted-by":"publisher","first-page":"102575","DOI":"10.1016\/j.jacadv.2025.102575","volume":"5","author":"D Do","year":"2026","unstructured":"Do, D. et al. FDA cardiovascular. indication expansion and dispensing of semaglutide\/tirzepatide in CVD patients with overweight\/obesity. JACC Adv. 5, 102575 (2026).","journal-title":"JACC Adv."},{"key":"3286_CR67","doi-asserted-by":"publisher","first-page":"3961","DOI":"10.1021\/acs.jcim.3c01619","volume":"64","author":"P Kamya","year":"2024","unstructured":"Kamya, P. et al. PandaOmics: an AI-driven platform for therapeutic target and biomarker discovery. J. Chem. Inf. Model. 64, 3961\u20133969 (2024).","journal-title":"J. Chem. Inf. Model."},{"key":"3286_CR68","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/nrd.2016.230","volume":"16","author":"R Santos","year":"2017","unstructured":"Santos, R. et al. A comprehensive map of molecular drug targets. Nat. Rev. Drug Discov. 16, 19\u201334 (2017).","journal-title":"Nat. Rev. Drug Discov."},{"key":"3286_CR69","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1007\/s00125-017-4318-z","volume":"60","author":"CJ Bailey","year":"2017","unstructured":"Bailey, C. J. Metformin: historical overview. Diabetologia 60, 1566\u20131576 (2017).","journal-title":"Diabetologia"},{"key":"3286_CR70","doi-asserted-by":"publisher","DOI":"10.1091\/mbc.E22-08-0377","volume":"33","author":"T Powers","year":"2022","unstructured":"Powers, T. The origin story of rapamycin: systemic bias in biomedical research and cold war politics. Mol. Biol. Cell 33, pe7 (2022).","journal-title":"Mol. Biol. Cell"},{"key":"3286_CR71","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1038\/ng1180","volume":"34","author":"VK Mootha","year":"2003","unstructured":"Mootha, V. K. et al. PGC-1\u03b1-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat. Genet. 34, 267\u2013273 (2003).","journal-title":"Nat. Genet."},{"key":"3286_CR72","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl Acad. Sci. USA 102, 15545\u201315550 (2005).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"3286_CR73","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-32552-1","volume":"13","author":"D Saul","year":"2022","unstructured":"Saul, D. et al. A new gene set identifies senescent cells and predicts senescence-associated pathways across tissues. Nat. Commun. 13, 4827 (2022).","journal-title":"Nat. Commun."},{"key":"3286_CR74","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-020-01990-9","volume":"21","author":"RA Avelar","year":"2020","unstructured":"Avelar, R. A. et al. A multidimensional systems biology analysis of cellular senescence in aging and disease. Genome Biol. 21, 91 (2020).","journal-title":"Genome Biol."},{"key":"3286_CR75","doi-asserted-by":"publisher","first-page":"e13041","DOI":"10.1111\/acel.13041","volume":"18","author":"K Chatsirisupachai","year":"2019","unstructured":"Chatsirisupachai, K., Palmer, D., Ferreira, S. & de Magalh\u00e3es, J. P. A human tissue-specific transcriptomic analysis reveals a complex relationship between aging, cancer, and cellular senescence. Aging Cell 18, e13041 (2019).","journal-title":"Aging Cell"},{"key":"3286_CR76","doi-asserted-by":"publisher","first-page":"D355","DOI":"10.1093\/nar\/gkp896","volume":"38","author":"M Kanehisa","year":"2010","unstructured":"Kanehisa, M., Goto, S., Furumichi, M., Tanabe, M. & Hirakawa, M. KEGG for representation and analysis of molecular networks involving diseases and drugs. Nucleic Acids Res. 38, D355\u2013D360 (2010).","journal-title":"Nucleic Acids Res."},{"key":"3286_CR77","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.cels.2015.12.004","volume":"1","author":"A Liberzon","year":"2015","unstructured":"Liberzon, A. et al. The Molecular Signatures Database (MSigDB) hallmark gene set collection. Cell Syst. 1, 417\u2013425 (2015).","journal-title":"Cell Syst."},{"key":"3286_CR78","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1093\/bioinformatics\/btr260","volume":"27","author":"A Liberzon","year":"2011","unstructured":"Liberzon, A. et al. Molecular signatures database (MSigDB) 3.0. Bioinformatics 27, 1739\u20131740 (2011).","journal-title":"Bioinformatics"},{"key":"3286_CR79","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1186\/s12859-017-1559-2","volume":"18","author":"A Fabregat","year":"2017","unstructured":"Fabregat, A. et al. Reactome pathway analysis: a high-performance in-memory approach. BMC Bioinf. 18, 142 (2017).","journal-title":"BMC Bioinf."},{"key":"3286_CR80","doi-asserted-by":"publisher","first-page":"btac757","DOI":"10.1093\/bioinformatics\/btac757","volume":"39","author":"Z Fang","year":"2023","unstructured":"Fang, Z., Liu, X. & Peltz, G. GSEApy: a comprehensive package for performing gene set enrichment analysis in Python. Bioinformatics 39, btac757 (2023).","journal-title":"Bioinformatics"},{"key":"3286_CR81","first-page":"55768","volume":"16","author":"C Weidner","year":"2017","unstructured":"Weidner, C. et al. A protocol for using gene set enrichment analysis to identify the appropriate animal model for translational research. J. Vis. Exp. 16, 55768 (2017).","journal-title":"J. Vis. Exp."},{"key":"3286_CR82","doi-asserted-by":"publisher","unstructured":"Borenstein, M., Hedges, L. V., Higgins, J. P. T. & Rothstein, H. R. Effect sizes based on means. in Introduction to Meta-Analysis (eds Borenstein, M., Hedges, L. V., Higgins, J. P. T. & Rothstein, H. R.) Ch. 4, 21\u201332 https:\/\/doi.org\/10.1002\/9780470743386.ch4 (Wiley, 2009).","DOI":"10.1002\/9780470743386.ch4"},{"key":"3286_CR83","doi-asserted-by":"publisher","first-page":"D433","DOI":"10.1093\/nar\/gki005","volume":"33","author":"C von Mering","year":"2005","unstructured":"von Mering, C. et al. STRING: known and predicted protein\u2013protein associations, integrated and transferred across organisms. Nucleic Acids Res. 33, D433\u2013D437 (2005).","journal-title":"Nucleic Acids Res."},{"key":"3286_CR84","doi-asserted-by":"publisher","unstructured":"Seabold, S. & Perktold, J. Statsmodels: econometric and statistical modeling with Python. scipy https:\/\/doi.org\/10.25080\/Majora-92bf1922-011 (2010).","DOI":"10.25080\/Majora-92bf1922-011"},{"key":"3286_CR85","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/s41592-019-0686-2","volume":"17","author":"P Virtanen","year":"2020","unstructured":"Virtanen, P. et al. SciPy 1.0: fundamental algorithms for scientific computing in Python. Nat. Methods 17, 261\u2013272 (2020).","journal-title":"Nat. Methods"},{"key":"3286_CR86","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.1109\/TVCG.2014.2346248","volume":"20","author":"A Lex","year":"2014","unstructured":"Lex, A., Gehlenborg, N., Strobelt, H., Vuillemot, R. & Pfister, H. UpSet: visualization of intersecting sets. IEEE Trans. Vis. Comput. Graph. InfoVis 20, 1983\u20131992 (2014).","journal-title":"IEEE Trans. Vis. Comput. Graph. InfoVis"},{"key":"3286_CR87","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1186\/s12859-015-0611-3","volume":"16","author":"H Heberle","year":"2015","unstructured":"Heberle, H., Meirelles, G. V., da Silva, F. R., Telles, G. P. & Minghim, R. InteractiVenn: a web-based tool for the analysis of sets through Venn diagrams. BMC Bioinf. 16, 169 (2015).","journal-title":"BMC Bioinf."}],"container-title":["Nature Biotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41587-026-03286-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41587-026-03286-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41587-026-03286-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T16:03:02Z","timestamp":1791388982000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41587-026-03286-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,7]]},"references-count":87,"alternative-id":["3286"],"URL":"https:\/\/doi.org\/10.1038\/s41587-026-03286-y","relation":{},"ISSN":["1087-0156","1546-1696"],"issn-type":[{"value":"1087-0156","type":"print"},{"value":"1546-1696","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,7]]},"assertion":[{"value":"17 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.Z. is the founder and chief executive officer of Insilico Medicine, a publicly traded (3696.HK) company developing and using generative AI for drug discovery and aging research. F.G., S.C., F.R., A.A, M.D., D.S. and H.C. are employees at Insilico Medicine. Insilico Medicine has developed a portfolio of therapeutic programs targeting fibrotic diseases, including rentosertib for IPF. The other authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}